Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Big pharma is set to keep signing bigger deals in 2024

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 27, 2024 12:01pm

165 Views

Post# 36109037

RE:Big pharma is set to keep signing bigger deals in 2024

June 27, 2024 - Biogen appears to be subtly signaling it has a larger appetite for M&A than previously stated.

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

https://endpts.com/biogen-is-pursuing-more-dealmaking-this-year-with-plans-to-spend-up-to-8b/

<< Previous

Bullboard Posts

Next >>

A PGM mining stock with value written all over it